Previous 10 | Next 10 |
- First quarter net product sales of $11.7 million - GOCOVRI® total prescriptions grew to approximately 5,820 in Q1 2019 - Phase 3 study of ADS-5102 (GOCOVRI) in walking impairment in patients with multiple sclerosis on course to complete in Q4 2019 EMERYVILLE, Calif., May...
EMERYVILLE, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that posters regarding GOCOVRI TM (amantadine) extende...
EMERYVILLE, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 first quarter financial results on Thursday, May 9, 2019, after market close. Subsequently, Adamas’ management team will host a conferenc...
With one candidate at Phase 3 of development, Trevi Therapeutics ( TRVI ) should interest IPO investors. Besides, the market will probably like the massive market opportunity. The total market for pruritus therapeutics was $11.09 billion in 2018. With that, it is not ideal that the company exp...
The FDA approves Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's Mavenclad (cladribine) tablets for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Merck KGaA ADR, Celgene Corporation, Roche Holding AG, Healthcare stocks news, Read more ...
The FDA approves Novartis' (NYSE: NVS ) Mayzent (siponimod) for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome (defined as a first episode of neurologic symptoms that lasts at least 24 hours and is caused by inflammation or demyelinatio...
Adamas Pharmaceuticals ( ADMS ), recently announced their Q4/2018 earnings report revealing another beat on revenue and EPS. The company publicized GOCOVRI net sales of roughly $13.3M for Q4 of 2018 (Figure 3), with approximately 5,730 prescriptions ( 4,740 in Q3 ) sold. Adamas was able to...
Gainers: Document Security Systems (NYSEMKT: DSS ) +57% . Cool Holdings (NASDAQ: AWSM ) +38% . Fuwei Films (NASDAQ: FFHL ) +30% . China Rapid Finance (NYSE: XRF ) +23% . Ctrip.com International (NASDAQ: CTRP ) +21% . Aqua Metals (NASDAQ: AQMS ) +18% . BioHiTech Global (NASDAQ: ...
Atlas Financial Holdings (NASDAQ: AFH ) -49% on Q4 earnings . More news on: Atlas Financial Holdings, Adamas Pharmaceuticals, Inc., China Finance Online Co. Limited, Stocks on the move, Read more ...
Adamas Pharmaceuticals (NASDAQ: ADMS ) slumps 29% premarket on light volume on the heels of its Q4 report that appeared to disappoint investors despite meeting preannounced Q4 results released in early January. Highlights: More news on: Adamas Pharmaceuticals, Inc., Healthc...
News, Short Squeeze, Breakout and More Instantly...
Adamas Pharmaceuticals Inc. Company Name:
ADMS Stock Symbol:
NASDAQ Market:
Adamas Pharmaceuticals Inc. Website:
Supernus Pharmaceuticals (NASDAQ: SUPN) recently announced that it's acquiring Adamas Pharmaceuticals (NASDAQ: ADMS) . In this Motley Fool Live video recorded on Oct. 13 , Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acq...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adamas Pharmaceuticals, Inc. Announces Definitive Agreement to be Acquired by Supernus Pharmaceuticals, Inc” Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) surged ove...
Supernus Pharmaceuticals Inc ( NASDAQ: SUPN ) recently announced that it had entered a definitive contract to acquire Adamas Pharmaceuticals ( NASDAQ: ADMS ). Supernus is to purchase this company a tender offer that was worth about $8.10 per share. The aggregate was roug...